Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.53 |
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | ARG2 | P78540 | 4/20 | 0.42 |
| ▸ | ARG1 | P05089 | 3/20 | 0.42 |
| ▸ | NOS2 | P35228 | 4/20 | 0.41 |
| ▸ | NOS1 | P29475 | 3/20 | 0.41 |
| ▸ | NOS3 | P29474 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25408373 | 1.00 | OTC (0.53) | OTCGSRNOD1DPP7ARG2 | |
| SCHEMBL27150870 | 0.82 | OTC (0.48) | OTCGSRNOD1DPP7ARG2 | |
| SCHEMBL25408044 | 0.82 | OTC (0.48) | OTCGSRNOD1DPP7ARG2 | |
| SCHEMBL25408052 | 0.82 | OTC (0.48) | OTCGSRNOD1DPP7ARG2 | |
| SCHEMBL13745390 | 0.81 | MEN1 (0.61) | OTCGSRNOD1DPP7ARG2 | |
| SCHEMBL1423420 | 0.81 | MEN1 (0.61) | OTCGSRNOD1DPP7ARG2 | |
| SCHEMBL27841191 | 0.80 | OTC (0.55) | OTCGSRNOD1DPP7ARG2 | |
| SCHEMBL12238274 | 0.80 | OTC (0.55) | OTCGSRNOD1DPP7ARG2 | |
| SCHEMBL5973446 | 0.80 | OTC (0.58) | OTCGSRNOD1DPP7ARG2 | |
| SCHEMBL12801966 | 0.80 | OTC (0.58) | OTCGSRNOD1DPP7ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295259-A1 | Conjugated Hepcidin Mimetics | PROTAGONIST THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295259-A1 | Conjugated Hepcidin Mimetics | HAMP, VIP, HDGF | OTC 2771/4885GSR 2345/4885NOD1 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.